Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06987916) titled 'Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma' on May 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
Condition:
B Cell Non-Hodgkin&Amp
#39
s Lymphoma
Intervention:
Drug: ssCART-19
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: April 22, 2025
Target Sample Size: 50
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06...